The data show that miR-23b can target both oncogenes and tumor suppressors, and its expression regulation in different types of cancers shows heterogeneity, which mainly acts through affecting signaling pathways, such as Wnt/β-catenin for tumorigenesis, and apoptotic proteins, such as BCL2 or oncogenes. Here, BCL2 is linked to cancer.